드러그인포 약품 상세정보

허가정보

항목

내용

청구코드(KD코드)
비급여점검코드
상한금액

641602230[A04303821] [보험코드에 따른 약품기본정보 직접조회]
\0 원/1g(2006.11.01)(현재약가)
\140 원/1g(2006.03.01)(변경전약가)
[상병코드조회]
[질병코드집 다운로드] [우리집건강주치의 바로가기]

빠른조회


요약정보	[효능] [용법] [금기] [신중투여] [이상반응]

상세정보	[효능] [용법] [경고] [금기] [신중투여] [이상반응] [일반주의] [상호작용] [임산부] [수유부] [소아] [고령자] [신장애환자] [간장애환자] [적용주의] [과량투여] [임상검사치] [보관] [기타]

제품성상

백색-미황백색의 연고로서 특이한 향기가 있다. [제형정보 확인]

포장·유통단위

자사포장단위에 따름

포장·코드단위

약품규격	단위	대표코드	표준코드	비고
20그램	1 개	8806416022306	8806416022313

주성분코드

337800COM [동일한 주성분코드를 가진 오리지날 또는 제네릭 의약품 조회]

대표코드

8806416022306

보관방법

밀폐용기, 실온보관

약리작용

[조회]

효능효과

[적응증 별 검색]

다음 증상의 완화 : 치질, 항문열상, 항문주위염, 가려움, 부종

용법용량

* 절대 임의복용하지 마시고 반드시 의사 또는 약사와 상담하시기 바랍니다.

[처방약어]
용법용법 용량
성인(15세이상) 1일 2-3회 환부에 적당량을 직접 바르거나 거즈나 린트포 등에 펴서 발라 붙인다.
항문내에 적용시 주입기를 사용하여 항문내에 짜 넣는다.

[BMI지수 계산] [Body Surface Area 계산] [Cockcroft-Gault GFR 계산] [MDRD GFR 계산]

[피해야 할 음식] [복용을 잊은 경우 대처법]

금기

환부가 화농되어 있는 환자

신중투여

이 약은 프로필렌글리콜을 함유하고 있으므로 이 성분에 과민하거나 알레르기 병력이 있는 환자에는 신중히 투여한다.

<다음 환자는 사용전에 의사 또는 약사와 상담할 것>
1) 지금까지 약에 의해 앨러지증상(발진, 발적, 부종등)을 일으킨 적이 있는 사람
2) 임부 또는 임신하고 있을 가능성이 있는 부인
3) 의사의 치료를 받고 있는 사람

이상반응

1) 이 약의 사용에 의하여 발적, 부종, 자극감 또는 화농 등의 증상이 나타날 경우에는 사용을 중지하고 의사 또는 약사와 상의할 것
2) 10일 정도 사용하여도 증상의 개선이 나타나지 않을 경우에는 사용을 중지하고 의사 또는 약사와 상의 할 것

[주요 이상반응정보]

일반적 주의

1) 정해진 용법, 용량을 지킬 것
2) 소아(15세 미만)에는 사용하지 말 것
3) 이 약은 항문부위에만 사용하고 안과용으로는 사용하지 말 것

보관 및 취급상의 주의

1)어린이의 손에 닿지 않는 곳에 보관할 것
2)직사광선을 피하고 될 수 있으면 습기가 적고 서늘한 곳에 밀전하여 보관할 것
3)오용을 피하고 품질을 보호 유지하기 위하여 다른 용기에 넣지 말 것

Related FDA Approved Drug

기준 성분:DIBUCAINE HYDROCHLORIDE
HEAVY SOLUTION NUPERCAINE (DIBUCAINE HYDROCHLORIDE)
기준 성분:ALUMINIUM CHLOROHYDROXY ALLANTOINATE

정보요약

드럭인포 의약품 요약/상세정보

코드 및 분류정보

항목	내용
성분코드	M081425/알란토인클로로히드록시알루미늄 5.0밀리그램 / M085126/이소프로필메칠페놀 1.0밀리그램 / M222965/디부카인염산염 3.0밀리그램 / M223298/프레드니솔론아세테이트 2.5밀리그램 / M223240/토코페롤아세테이트 10.0밀리그램 /
주성분코드	337800COM [동일한 주성분코드를 가진 오리지날 또는 제네릭 의약품 조회]
대표코드	8806416022306
BIT 약효분류	혈관강화제, 정맥류 치료제, 치질약(Capillary stabilizer, Phlebitis, Varicose veins, Hemorrhoidal)
ATC 코드	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE / C05A [코드분류상세설명] [ATC코드예측]
복지부분류코드	256 (치질용제 )
주성분코드 분석 및 중복처방 검토	[주성분코드 분석 및 중복처방 검토]
Drugs By Indication	[전체보기]
Drugs By Classification	[전체보기]

제품정보

항목	내용
청구코드(KD코드) 비급여점검코드 상한금액	641602230[A04303821] [보험코드에 따른 약품기본정보 직접조회] \0 원/1g(2006.11.01)(최신약가) \140 원/1g(2006.03.01)(변경전약가) [상병코드조회] [질병코드집 다운로드]
제품성상	백색-미황백색의 연고로서 특이한 향기가 있다. [제형정보 확인]
포장·유통단위	자사포장단위에 따름
보관방법	밀폐용기, 실온보관
동일주성분코드 검색순위	유료정보입니다.

복약정보

항목

내용

LACTmed 바로가기

[바로가기]

약리작용

유료정보입니다.

축약복약지도

유료정보입니다.

복약지도

유료정보입니다.

임부에대한투여

*	전체임신 기간별로 여러등급이 존재할 수 있으며 가장 위험도가 높은 정보만 보여집니다. 단, 복합제의 경우 모든 복합제성분에 대한 임부투여등급이 표시된것은 절대 아니며 표시된것중에 가장 위험도가 높은 정보만 나타납니다.

FDA : C등급

*	상기 임부투여에 대한 정보는 전산처리 되면서 입력 오류 가능성이 존재합니다. 오류 가능성을 최소화하기 위하여 많은 노력을 기울이고 있으나, 그 정확성에 대하여 확신을 드릴 수 없습니다. 이에 대해 회사는 책임을 지지 않습니다.
*	반드시 공신력 있는 문헌을 다시 한번 참고 하시기 바라며 의사 또는 약사의 판단에 따라 투여여부가 결정되어야 합니다.

Pharmacokinetics

유료정보입니다.

제형별 복약지도

[연고]

보관상 주의

조제시 주의

심사정보

항목	내용
DUR 관련 고시	[병용연령금기 의약품 / 임부금기 의약품 / 비용효과적 함량 의약품 / 안전성 관련 급여중지 의약품]

학술정보

항목	내용
DUR (의약품사용평가)	병용금기 : 고시된 병용금기 내용은 없습니다. [상호작용/병용금기검색] 연령대금기 : 고시된 연령금기 내용은 없습니다. [연령대금기상세검색]
Mechanism of Action	Aluminium에 대한 Mechanism_Of_Action 정보 Aluminum Acetate is an astringent. An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application. The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied. Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot. Dibucaine에 대한 Mechanism_Of_Action 정보 Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade. Prednisolone에 대한 Mechanism_Of_Action 정보 Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.
Pharmacology	Aluminium에 대한 Pharmacology 정보 Not Available Dibucaine에 대한 Pharmacology 정보 Dibucaine is an amide-type local anesthetic, similar to lidocaine. Prednisolone에 대한 Pharmacology 정보 Prednisolone is a synthetic glucocorticoid used as antiinflammatory or immunosuppressive agent. Prednisolone is indicated in the treatment of various conditions, including congenital adrenal hyperplasia, psoriatic arthritis, systemic lupus erythematosus, bullous dermatitis herpetiformis, seasonal or perennial allergic rhinitis, allergic corneal marginal ulcers, symptomatic sarcoidosis, idiopathic thrombocytopenic purpura in adults, leukemias and lymphomas in adults, and ulcerative colitis. Glucocorticoids are adrenocortical steroids and cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.
Metabolism	Dibucaine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2D6 (CYP2D6)Cholinesterase Prednisolone에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4)
Protein Binding	Aluminium에 대한 단백결합 정보 Not Available Dibucaine에 대한 단백결합 정보 Not Available Prednisolone에 대한 단백결합 정보 Very high (>90%)
Half-life	Aluminium에 대한 반감기 정보 Not Available Dibucaine에 대한 반감기 정보 Not Available Prednisolone에 대한 반감기 정보 2-3 hours
Absorption	Dibucaine에 대한 Absorption 정보 In general, ionized forms (salts) of local anesthetics are not readily absorbed through intact skin. However, both nonionized (bases) and ionized forms of local anesthetics are readily absorbed through traumatized or abraded skin into the systemic circulation. Prednisolone에 대한 Absorption 정보 Readily absorbed by gastrointestinal tract, peak plasma concentration is reached 1-2 hours after administration.
Pharmacokinetics	Dibucaine HCl의 약물동력학자료 작용발현시간 : 15분 이내 작용지속시간 : 2-4 시간 흡수 : 손상되지 않은 피부에 적용시 흡수는 매우 적지만, 점막이나 손상된 피부로부터는 잘 흡수된다. Tocopherol Acetate의 약물동력학자료 흡수 : 경구 : 소장으로부터 흡수되는 데에는 담즙이 필요하다. 흡수 저하 : 흡수장애 환자, 저체중 미숙아, 고용량 투여 유화제제보다 수용성 제제가 더 잘 흡수된다. 분포 : 모든 조직에 분포하며, 특히 지방조직에 고농도로 분포하고 저장된다. 대사 : 간에서 glucuronides 포합 소실 : 주로 담즙을 통해 (70-80%) 배설된다. Prednisolone acetate의 약물동력학자료 단백결합 : 65∼91% (용량 의존적) 대사 : 일차적으로 간에서 대사되나 대부분의 조직에서도 대사가 일어나며 비활성형 대사체가 생성된다. 반감기 : 3.6시간 생리적 반감기 : 18-36시간 말기 신질환 환자에서의 반감기 : 3∼5시간 소실 : 대부분 glucuronides, sulfates 포합체나 비포합 대사체로 신배설 된다.
Biotransformation	Aluminium에 대한 Biotransformation 정보 Not Available Dibucaine에 대한 Biotransformation 정보 Primarily hepatic. Prednisolone에 대한 Biotransformation 정보 Excreted in the urine as either free or glucoconjugate.
Toxicity	Dibucaine에 대한 Toxicity 정보 Subcutaneous LD₅₀ in rat is 27 mg/kg. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. Prednisolone에 대한 Toxicity 정보 LD₅₀=500 mg/kg (oral, rat), short-term side effects include high blood glucose levels and fluid retention. Long term side effects include Cushing's syndrome, weight gain, osteoporosis, glaucoma, type II diabetes and adrenal suppression.
Drug Interactions	Aluminium에 대한 Drug_Interactions 정보 Cyclosporine Synercid increases the effect of cyclosporineAmlodipine This combination presents an increased risk of toxicityArsenic trioxide This combination presents an increased risk of toxicityAstemizole This combination presents an increased risk of toxicityAtorvastatin This combination presents an increased risk of toxicityCarbamazepine This combination presents an increased risk of toxicityCerivastatin This combination presents an increased risk of toxicityCisapride This combination presents an increased risk of toxicityClarithromycin This combination presents an increased risk of toxicityDelavirdine This combination presents an increased risk of toxicityDiazepam This combination presents an increased risk of toxicityDihydroquinidine barbiturate This combination presents an increased risk of toxicityDiltiazem This combination presents an increased risk of toxicityDisopyramide This combination presents an increased risk of toxicityDocetaxel This combination presents an increased risk of toxicityDofetilide This combination presents an increased risk of toxicityDroperidol This combination presents an increased risk of toxicityErythromycin This combination presents an increased risk of toxicityEtoposide This combination presents an increased risk of toxicityFelbamate This combination presents an increased risk of toxicityFelodipine This combination presents an increased risk of toxicityFlecainide This combination presents an increased risk of toxicityFoscarnet This combination presents an increased risk of toxicityFosphenytoin This combination presents an increased risk of toxicityGatifloxacin This combination presents an increased risk of toxicityGrepafloxacin This combination presents an increased risk of toxicityHalofantrine This combination presents an increased risk of toxicityIndinavir This combination presents an increased risk of toxicityIsradipine This combination presents an increased risk of toxicityLercanidipine This combination presents an increased risk of toxicityLevofloxacin This combination presents an increased risk of toxicityLosartan This combination presents an increased risk of toxicityLevomethadyl Acetate This combination presents an increased risk of toxicityLidocaine This combination presents an increased risk of toxicityLovastatin This combination presents an increased risk of toxicityMethylprednisolone This combination presents an increased risk of toxicityMidazolam This combination presents an increased risk of toxicityMoexipril This combination presents an increased risk of toxicityMoxifloxacin This combination presents an increased risk of toxicityNevirapine This combination presents an increased risk of toxicityNicardipine This combination presents an increased risk of toxicityNifedipine Synercid increases the effect of ziprasidoneNimodipine This combination presents an increased risk of toxicityNisoldipine This combination presents an increased risk of toxicityOctreotide This combination presents an increased risk of toxicityPaclitaxel This combination presents an increased risk of toxicityPentamidine This combination presents an increased risk of toxicityQuetiapine This combination presents an increased risk of toxicityQuinidine This combination presents an increased risk of toxicityQuinidine barbiturate This combination presents an increased risk of toxicityRitonavir This combination presents an increased risk of toxicitySalmeterol This combination presents an increased risk of toxicitySimvastatin This combination presents an increased risk of toxicityTacrolimus This combination presents an increased risk of toxicityTamoxifen This combination presents an increased risk of toxicityTeniposide This combination presents an increased risk of toxicityTerfenadine This combination presents an increased risk of toxicityTizanidine This combination presents an increased risk of toxicityVenlafaxine This combination presents an increased risk of toxicityVerapamil This combination presents an increased risk of toxicityVinblastine This combination presents an increased risk of toxicityVincristine This combination presents an increased risk of toxicityVindesine This combination presents an increased risk of toxicityVinorelbine This combination presents an increased risk of toxicity Dibucaine에 대한 Drug_Interactions 정보 Methotrexate The NSAID increases the effect and toxicity of methotrexateLithium The NSAID increases serum levels of lithiumAcenocoumarol The NSAID increases the anticoagulant effect Prednisolone에 대한 Drug_Interactions 정보 Ambenonium The corticosteroid decreases the effect of anticholinesterasesEdrophonium The corticosteroid decreases the effect of anticholinesterasesNeostigmine The corticosteroid decreases the effect of anticholinesterasesPyridostigmine The corticosteroid decreases the effect of anticholinesterasesWarfarin The corticosteroid alters the anticoagulant effectAcenocoumarol The corticosteroid alters the anticoagulant effectDicumarol The corticosteroid alters the anticoagulant effectAnisindione The corticosteroid alters the anticoagulant effectMidodrine Increased arterial pressureAspirin The corticosteroid decreases the effect of salicylatesBismuth Subsalicylate The corticosteroid decreases the effect of salicylatesSalicylate-magnesium The corticosteroid decreases the effect of salicylatesSalicylate-sodium The corticosteroid decreases the effect of salicylatesSalsalate The corticosteroid decreases the effect of salicylatesTrisalicylate-choline The corticosteroid decreases the effect of salicylatesTalbutal The barbiturate decreases the effect of the corticosteroidSecobarbital The barbiturate decreases the effect of the corticosteroidQuinidine barbiturate The barbiturate decreases the effect of the corticosteroidPrimidone The barbiturate decreases the effect of the corticosteroidPhenobarbital The barbiturate decreases the effect of the corticosteroidPentobarbital The barbiturate decreases the effect of the corticosteroidMethylphenobarbital The barbiturate decreases the effect of the corticosteroidMethohexital The barbiturate decreases the effect of the corticosteroidHexobarbital The barbiturate decreases the effect of the corticosteroidHeptabarbital The barbiturate decreases the effect of the corticosteroidDihydroquinidine barbiturate The barbiturate decreases the effect of the corticosteroidButethal The barbiturate decreases the effect of the corticosteroidButalbital The barbiturate decreases the effect of the corticosteroidButabarbital The barbiturate decreases the effect of the corticosteroidAprobarbital The barbiturate decreases the effect of the corticosteroidAmobarbital The barbiturate decreases the effect of the corticosteroidChlorotrianisene The estrogenic agent increases the effect of the corticosteroidClomifene The estrogenic agent increases the effect of the corticosteroidDiethylstilbestrol The estrogenic agent increases the effect of the corticosteroidEstradiol The estrogenic agent increases the effect of the corticosteroidEstriol The estrogenic agent increases the effect of the corticosteroidConjugated Estrogens The estrogenic agent increases the effect of the corticosteroidEstrone The estrogenic agent increases the effect of the corticosteroidEstropipate The estrogenic agent increases the effect of the corticosteroidEthinyl Estradiol The estrogenic agent increases the effect of the corticosteroidMestranol The estrogenic agent increases the effect of the corticosteroidQuinestrol The estrogenic agent increases the effect of the corticosteroidEthotoin The enzyme inducer decreases the effect of the corticosteroidFosphenytoin The enzyme inducer decreases the effect of the corticosteroidMephenytoin The enzyme inducer decreases the effect of the corticosteroidPhenytoin The enzyme inducer decreases the effect of the corticosteroidRifampin The enzyme inducer decreases the effect of the corticosteroidItraconazole The imidazole increases the effect and toxicity of the corticosteroidKetoconazole The imidazole increases the effect and toxicity of the corticosteroid
CYP450 Drug Interaction	[CYP450 Table직접조회]
Food Interaction	Prednisolone에 대한 Food Interaction 정보 Take with food to reduce gastric irritation.Avoid alcohol. Avoid caffeine.
Drug Target	[Drug Target]
Description	Aluminium에 대한 Description 정보 A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98. [PubChem] Dibucaine에 대한 Description 정보 A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) Prednisolone에 대한 Description 정보 A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]
Drug Category	Aluminium에 대한 Drug_Category 정보 Not Available Dibucaine에 대한 Drug_Category 정보 Anesthetics, Local Prednisolone에 대한 Drug_Category 정보 Adrenergic AgentsAnti-inflammatory AgentsAntineoplastic AgentsAntineoplastic Agents, HormonalGlucocorticoids
Smiles String Canonical	Aluminium에 대한 Smiles_String_canonical 정보 [Al] Dibucaine에 대한 Smiles_String_canonical 정보 CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC Prednisolone에 대한 Smiles_String_canonical 정보 CC12CC(O)C3C(CCC4=CC(=O)C=CC34C)C1CCC2(O)C(=O)CO
Smiles String Isomeric	Aluminium에 대한 Smiles_String_isomeric 정보 [Al] Dibucaine에 대한 Smiles_String_isomeric 정보 CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC Prednisolone에 대한 Smiles_String_isomeric 정보 C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
InChI Identifier	Aluminium에 대한 InChI_Identifier 정보 InChI=1/Al Dibucaine에 대한 InChI_Identifier 정보 InChI=1/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)/f/h21H Prednisolone에 대한 InChI_Identifier 정보 InChI=1/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
Chemical IUPAC Name	Aluminium에 대한 Chemical_IUPAC_Name 정보 aluminum Dibucaine에 대한 Chemical_IUPAC_Name 정보 2-butoxy-N-(2-diethylaminoethyl)quinoline-4-carboxamide Prednisolone에 대한 Chemical_IUPAC_Name 정보 (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
Drug-Induced Toxicity Related Proteins	PREDNISOLONE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:DNA topoisomerase 1 Drug:prednisolone Toxicity:appearance of apoptotic cells. [바로가기]

사용자컨텐츠

항목

내용

핵심 요약 정보